Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes
Phase 2
Completed
- Conditions
- Dyslipidemia/Glucose Metabolism Disorder
- Registration Number
- NCT00349128
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 382
Inclusion Criteria
- Type 2 diabetes mellitus
Exclusion Criteria
- Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose > 300 mg/dL - Triglycerides > 500 mg/dL
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in fasting triglycerides.
- Secondary Outcome Measures
Name Time Method Assessment of lipid and glucose metabolisms.
Trial Locations
- Locations (51)
Site 201
🇵🇱Katowice, Poland
Site 203
🇵🇱Katowice, Poland
Site 202
🇵🇱Warszawa, Poland
Site 204
🇵🇱Zabrze, Poland
Site 111
🇺🇦Dnipropetrovsk, Ukraine
Site 113
🇺🇦Dnipropetrovsk, Ukraine
Site 108
🇺🇦Kharkiv, Ukraine
Site 109
🇺🇦Kharkiv, Ukraine
Site 101
🇺🇦Kyiv, Ukraine
Site 102
🇺🇦Kyiv, Ukraine
Scroll for more (41 remaining)Site 201🇵🇱Katowice, Poland